Background/Aims: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran. Methods: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals. Results: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for ≤100 days had a higher incidence of GI bleeding than those who were on it for ＞100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for ≤100 days was 8.2 times higher compared to those who were on the drug for ＞100 days. The incidence of GI bleeding in patients ＞65 years old was higher than in those ＜65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0% vs. 38.1%, p=0.014). Conclusions: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigtran were the first 100 days, age ＞65 years, and a history of previous GI bleeding. (Korean J Gastroenterol 2015;65:205-214) 
INTRODUCTION
Vitamin K antagonists have been used to decrease the risk of thromboembolic events in many clinical settings including atrial fibrillation; however, owing to the need for frequent laboratory monitoring, multiple drug-drug interactions and food-drug interactions, they are frequently not used, discontinued, or frequently suboptimal. 1, 2 Thus, the need for new oral anticoagulation agents with better efficacy and safety profile is emerging. Dabigatran is an oral prodrug that is rapidly converted to the active from by serum esterases. Its bioavailability is very low (6.5%) and reaches the peak plasma concentration levels within 2 hours after administration. 3, 4 The elimination half-life of dabigatran is 14-17 hours, thus, a twice-daily dos-
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The Korean Journal of Gastroenterology ing is needed to reduce the variability of the anticoagulant effect. 3, 4 It is administered in fixed doses and excreted mainly by the kidneys (80%), therefore, the half-life may increase up to 35 hours in severe renal impairment. [3] [4] [5] Dabigatran is dialyzable due to its small molecular nature and low plasma protein binding capacity. 5 It is a direct thrombin inhibitor that reversibly blocks the active site of thrombin, at both the free and fibrin-bound form. It does not require any laboratory monitoring. Dabigatran is not metabolized via the cytochrome P450 system, and therefore, its drug and food interactions are minimal. 6 Potent inhibitors of P-glycoprotein such as quinidine, amiodarone, dronedarone, verapamil, and ketoconazole are the main drugs that can affect its metabolism and prolong its half-life. 6 Dabigatran is available in two dose preparations (150 mg, 110 mg); however, the 110 mg-dose is not approved by the FDA and is not available in the US.
Instead, the 75 mg dose is available in the US and is indicated in those with impaired renal function (creatinine clearance of 15-30 mL/min), and the concomitant use of strong P-glycoprotein inhibitors such as dronedarone.
Despite demonstration of the non-inferiority of dabigatran to warfarin and having less intracranial bleeding, results regarding the risk of gastrointestinal (GI) bleeding are conflicting. Our hypothesis was that the risk of GI bleeding while on dabigatran was higher when compared to warfarin. The aim of our study was to compare the risk of GI bleeding in patients taking dabigatran with those receiving warfarin and identify any risk factors for development of GI bleeding in patients on dabigatran.
SUBJECTS AND METHODS
In this retrospective cohort study, we examined the medical records of all patients who were started on dabigatran from October 2010 to October 2012, and compared to a control group of patients who were started on warfarin during that period in a 1 : 1 fashion. Patients who were on dabigatran for ≥3 days or on warfarin for ≥4 days were included in the study. A chi-square analysis was used for parameters in the secondary aims.
RESULTS

Patients
A total of 417 patients were identified, of whom 208 pa- switching to rivaroxaban, 1; percutaneous endoscopic gastrostomy tube placement, 1; and an unknown reason, 1),
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Gastrointestinal bleeding events
GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375) ( Table 2 ). The odds of bleeding in patients who were on warfarin were 2.2 times higher than in those on dabigatran. The mean age of patients who developed GI bleeding was 79.20 years and 75.86 years in the dabigatran and warfarin groups, respectively (p=0.441). The majority of patients in both groups were female (80.0% and 61.9%, respectively; p=0.428) and white (80% and 100%, respectively; p=0.097). GI bleeding occurred in 3 patients taking dabigatran 75 mg twice daily. The mean duration of using dabigatran until the GI bleeding event was 108.50 days compared to 188.86 days in the warfarin group (p=0.189). In patients who developed GI bleeding, it occurred in the first 100 days of using the drug in 80.0% of patients in the dabigatran group compared to 42.8% in the warfarin group (p=0.052).
In the dabigatran group, the concomitant use of aspirin, thienopyridines, dual antiplatelet agents, and NSAIDs was not statistically different between the two groups of patients who developed GI bleeding (all p＞0.05).
Multivariate analysis using logistic regression analysis was performed to determine the risk factors for GI bleeding in patients on dabigatran (Table 3) . Cox regression analysis was also used, which demonstrated results similar to those Fig. 1 . Cumulative gastrointestinal bleeding free survival in total subjects, including both warfarin and dabigatran groups. Fig. 2 . The rate of gastrointestinal bleeding for both drugs over time. Fig. 3 . The survival rate without gastrointestinal bleeding for both drugs over time.
of logistic regression. There was a higher incidence of GI bleeding during the first 100 days when compared to ＞100 days of drug use (p=0.0007) regardless of whether the patients were on dabigatran alone or with concomitant use of antiplatelet agents (single or dual) or NSAIDs. The odds of GI bleeding in patients who were on dabigatran for ≤100 days was 8.2 times higher when compared to those on the drug ＞100 days. The incidence of GI bleeding in patients ＞65
years old was higher than in those ≤65 years old (p=0.0453, OR=3 at 882 days from starting to take either medication (Fig. 1) .
Overall, the mean number of days until GI bleeding occurred 2) . A log rank test was used for comparison of GI bleeding rate between dabigatran and warfarin groups which revealed significant difference in survival over time between the two groups (log rank test, p=0.048) as shown in Fig. 3 . The lower GI tract was the most common site of GI bleeding in the dabigatran group (80.0% in the dabigatran group vs. 38.1% in the warfarin group, p=0.014) ( Tables 2, 4 ).
Secondary aims
Major non GI bleeding events, as defined as bleeding events that required hospitalization and cessation of the anticoagulation agent, occurred in 3 patients (1.4%) in the dabigatran group (hematuria, 2 and vaginal bleeding, 1) when
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The Korean Journal of Gastroenterology on dabigatran and warfarin, respectively (p=0.751). None of the patients suffered from intracranial hemorrhage in the dabigatran group but one patient had this event in the warfarin group (p=1). Seven patients (3.4%) on dabigatran and 15 patients (7.2%) on warfarin died while on therapy (p=0.082).
The causes of death were sudden cardiac death (2), sepsis (2), respiratory failure (2), and congestive heart failure (1) in the dabigatran group, whereas sudden cardiac (2), sepsis (3), respiratory failure (1), congestive heart failure (1), cancer (lung, ovarian, vulvar, leukemia) (7), and retroperitoneal bleeding (1) in the warfarin group. No death was related to GI bleeding. warfarin group (p＜0.001), but it was 1.12% with a dabigatran dose of 110 mg twice daily, which was not significantly different from the warfarin group. 1 Also, in the RE-COVER study, the risk of any GI bleeding events was 4.2% and 2.8%
with the use of dabigatran and warfarin, respectively.
2
In our study, the risk of GI bleeding was higher in both groups when compared to the above mentioned studies. This may be explained by use of a different definition for GI bleeding in our study (GI bleeding was defined as any bleeding in the GI tract that required hospitalization) which may include major and some minor GI bleeding events in other studies.
For example, in the RE-LY study, the definition of "reduction in the hemoglobin level by at least 2 g/dL or transfusion of at least 2 units of blood" for major GI bleeding, and minor for any other GI bleeding events were used. Also, in our study, the concomitant use of aspirin, thienopyridines, and dual antiplatelet agents in both groups combined were 48.1%, 14.2%, and 8.4%, respectively, which were much higher compared to the RE-LY study (32%, 1.9%, and 4.5%, respectively). In the RE-LY study, the concomitant use of aspirin, thienopyridines, or dual antiplatelet agents was associated with increased risk of minor and major bleeding. 7, 8 However, in our study the use of antiplatelet agents did not increase the risk of GI bleeding with dabigatran use, which could be explained by using these agents more often in other studies which obviously requires a larger sample to show the difference. Although the average age of our patients did not differ from other studies, the proportion of our patients who were older than 85 years was higher when compared to other studies. In our study, 16 .8% of patients in the dabigatran group and 13.9% in the warfarin group were older than 85 years when compared to 0.8% and 7.6% in the Danish registry. 9 The risk of bleeding, including GI bleeding, increases with increased age with both dabigatran and warfarin. 8 However, despite this high incidence of GI bleeding in both groups in our study, the risk was lower in the dabigatran group when compared to the warfarin group. First, dabigatran dose of 75 mg twice daily is recommended in patients with GFR ≤30 mL/min/1.73 m 2 . In our study, this dose was used in 42 patients (20.2%), but GFR was ≤30 mL/min/1.73 m 2 in only 10 patients (4.8%). This might explain the lower GI bleeding rate with dabigatran use since a lower dose was used more often than the dose recommended by the FDA. The concomitant use of P-glycoprotein inhibitors such as quinidine, amiodarone, dronedarone, verapamil, and ketoconazole (another category where the dose of 75 mg is recommended by the FDA) was not assessed in our study. The risk of major or minor bleeding events, including GI bleeding, with dabigatran is dose-dependent as confirmed in the RE-LY study and other studies. 1, 10 The risk of GI bleeding was lower with the dose of 110 mg when compared to 150 mg (1.12% vs. 1.51%, p=0.007). 1, 10 Another explanation for the lower incidence of GI bleeding with dabigatran when compared to warfarin is the shorter mean duration of being on the active drug (289.7 days in the dabigatran group vs. 355.9 days in the warfarin group). It has been shown that the longer the duration of anticoagulant use, the higher GI bleeding risk, at least for warfarin. The third explanation is that the time in therapeutic range (TTR) for INR for patients on warfarin might have been low in our patients. An INR range of 2-3 is considered the optimal therapeutic range that has shown a maximum benefit with acceptable adverse effects. It has been shown that a minimum TTR of 58% is needed to achieve the benefit from warfarin. 11 A low TTR is associated with increased risk of mortality, hospitalization, stroke and other thromboembolic events, as well as major bleeding events. [12] [13] [14] A wide variation in TTR has been reported in different studies, countries, medical centers, warfarin clinics and community settings, and it has been reported to be as low as 28.6%. 11, [15] [16] [17] The INR has been reported to be above the therapeutic range in as high as 30% of the time. 17 We did not check the INR status in our patients, and therefore it is possible that our patients had low TTR which could have affected the efficacy and safety of warfarin. However, in the recent study from the Danish registry by Larsen et al., 9 the overall risk of GI bleeding was not significantly different between dabigatran and warfarin groups (p=0.075), and the risk was even lower with the dabigatran dose of 110 mg twice daily when compared to warfarin (hazard ratio=0.60, 95% CI=0.37-0.93) ( Table 6 ). In a recent study from the reports to FDA to Mini-Sentinel initiative, published in April 2013, the risk of GI bleeding was lower with the use of dabigatran when compared to warfarin (1.6 events per 100,000 days at risk vs. 3.1 events per 100,000 days at risk), which is similar to our study (Table 6) . 18 Multivariate analysis showed that the risk of GI bleeding in- The Korean Journal of Gastroenterology age may explain the increased risk of GI bleeding in the elderly. However, this risk diminished between dabigatran and warfarin after age 85 years, which was statistically insignificant in our study.
In our study the risk of GI bleeding was higher during the first 100 days of the commencement of dabigatran.
Dabigatran achieves the anticoagulant effects faster than warfarin. The TTR is low in the first few months of starting warfarin as shown in different studies. For example, in the RE-COVER trial, the TTR was 53% in the first month compared to 66% in the sixth month. 2 Dabigatran most likely unmasks the pre-existing diseases such as colon cancer during the first 100 days in a way faster than warfarin. Interestingly, in our study, there were two cases of ischemic colitis in the dabigatran group. It is unclear whether this was a coincidence or there is a causality relationship between dabigatran and development of ischemic colitis. In our study, patients with a previous history of GI bleeding had increased risk of GI bleeding events with dabigatran by 6.3 times. This could also be due to unmasking pre-existing GI disease.
The lower GI tract was the most common site (80.0%) for GI bleeding events in the dabigatran group compared to warfarin (38.1%) ( Table 3 ). In the RE-LY trial, the site of GI bleeding was the lower GI tract in 47% in the dabigtran group compared to 25% in the warfarin group. 8 One proposed mechanism for the increased rate of lower GI bleeding with dabigatran use is the local effect of the unabsorbed dabigatran on the pre-existing diseased mucosa in the lower GI tract.
Dabigatran etexilate has a low bioavailability (6.5%), which means a higher local concentration of the unabsorbed dabigatran in the lower GI tract which may locally convert, by either colonic epithelial or bacterial enzymes, to active metabolites which may potentially lead to bleeding. On the other hand, warfarin has a high bioavailability and any unabsorbed warfarin cannot cause bleeding because warfarin needs to be metabolized by liver enzymes to achieve its anticoagulation effects. 8 In the secondary outcomes, major bleeding events other than GI bleeding, cerebrovascular events, intracranial hemorrhage, thromboembolic events, and all-cause mortality were lower numerically but not significant statistically with dabigatran use as compared to warfarin. Surprisingly, the risk of acute coronary disease requiring angioplasty, with or without stenting, or heart surgery was lower in the dabigatran group as compared to warfarin, as opposed to the RE-LY study or even its revised result. 1, 19 In another study, the risk of ACS and acute myocardial infarction was similar between dabigatran and warfarin. 2 However, the latest Danish registry study showed a low risk of coronary artery disease in the dabigatran group when compared to warfarin, which is in agreement with the result of our study. 9 This study has several limitations. Primarily, the size of the study was small when compared to other studies. Second, it was a retrospective study which carries its own bias and weaknesses. However, this study reflects the real-world scenario.
Our study provides data that support the safety of dabigatran including lower GI bleeding events relative to warfarin.
Dabigatran is a more convenient drug than warfarin for both patients and health care providers. Our study represents another step towards the end of the warfarin era, similar to the end of the golden era of unfractionated heparin with the introduction of low-molecular weight heparins a few decades ago. Although dabigatran is a safer drug than warfarin, physicians should exercise caution while treating their patients with any anticoagulation agents.
